Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen submits application to FDA seeking approval of Repatha injection
Approved by the FDA on Aug. 27, 2015, Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that reduces
Approved by the FDA on Aug. 27, 2015, Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that reduces
Intramuscular vaccinations of VB10.16 will be offered to patients at three different time points. Vaccibody will assess two different dosing schedules in the first phase of the study
The company treated 736 patients with type-2 diabetes inadequately controlled over a 30-week period. Full results of the trial will be communicated in a future scientific forum. The
The companies have signed a license, development and commercialization agreement, under which Mundipharma will have exclusive product rights in 39 European markets including France, Germany, Italy and Spain.
Under the partnership, the companies will jointly select two preclinical drug candidates, one in inflammation and the other in oncology. Two preclinical drug candidates will be targeted, one
The product is currently in Phase 2a clinical trial to treat hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant MRSA strains. Aridis
Situated in Boulder, Colorado, the LakeCentre plant will increase manufacturing and production capacity to support AstraZeneca’s portfolio of biologics medicines. AstraZeneca aims to undertake refurbishment and infrastructure improvements
Patient dosing and follow-up is underway and the company expects to reveal top-line results later this year. SMT19969 is a novel, oral antibiotic designed to selectively target C.
SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of BPDCN, AML, and other hematologic cancers. It
The partnership will enable the pharmaceutical firm to access IBM’s Watson Health Cloud to benefit patients and healthcare providers. IBM’s Watson is the first commercially available cognitive computing